Literature DB >> 36000838

Mature Rotavirus Particles Contain Equivalent Amounts of 7meGpppG-Capped and Noncapped Viral Positive-Sense RNAs.

Joaquin Moreno-Contreras1, Liliana Sánchez-Tacuba2,3,4, Carlos F Arias1, Susana López1.   

Abstract

Viruses have evolved different strategies to overcome their recognition by the host innate immune system. The addition of caps at their 5' RNA ends is an efficient mechanism not only to ensure escape from detection by the innate immune system but also to ensure the efficient synthesis of viral proteins. Rotavirus mRNAs contain a type 1 cap structure at their 5' end that is added by the viral capping enzyme VP3, which is a multifunctional protein with all the enzymatic activities necessary to add the cap and also functions as an antagonist of the 2'-5'-oligoadenylate synthetase (OAS)/RNase L pathway. Here, the relative abundances of capped and noncapped viral RNAs during the replication cycle of rotavirus were determined. We found that both classes of rotaviral plus-sense RNAs (+RNAs) were encapsidated and that they were present in a 1:1 ratio in the mature infectious particles. The capping of viral +RNAs was dynamic, since different ratios of capped and noncapped RNAs were detected at different times postinfection. Similarly, when the relative amounts of capped and uncapped viral +RNAs produced in an in vitro transcription system were determined, we found that the proportions were very similar to those in the mature viral particles and in infected cells, suggesting that the capping efficiency of VP3, both in vivo and in vitro, might be close to 50%. Unexpectedly, when the effect of simultaneously knocking down the expression of VP3 and RNase L on the cap status of viral +RNAs was evaluated, we found that, even though at late times postinfection there was an increased proportion of capped viral RNAs in infected cells, the viral particles isolated from this condition contained equal ratios of capped and noncapped viral RNA, suggesting that there might be selective packaging of capped and noncapped RNAs. IMPORTANCE Rotaviruses have a genome composed of 11 segments of double-stranded RNA. Whether all 5' ends of the positive-sense genomic RNAs contained in the mature viral particles are modified by a cap structure is unknown. In this work, we characterized the relative proportions of capped and noncapped viral RNAs in rotavirus-infected cells and in viral particles by using a direct quantitative assay. We found that, independent of the relative proportions of capped/noncapped RNAs present in rotavirus-infected cells, there were similar proportions of these two kinds of 5'-modified positive-sense RNAs in the viral particles.

Entities:  

Keywords:  RNA modifications; VP3; capping enzymes; dsRNA; rotavirus

Mesh:

Substances:

Year:  2022        PMID: 36000838      PMCID: PMC9472601          DOI: 10.1128/jvi.01151-22

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  35 in total

1.  Rotavirus Controls Activation of the 2'-5'-Oligoadenylate Synthetase/RNase L Pathway Using at Least Two Distinct Mechanisms.

Authors:  Liliana Sánchez-Tacuba; Margarito Rojas; Carlos F Arias; Susana López
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

2.  Analysis of the kinetics of transcription and replication of the rotavirus genome by RNA interference.

Authors:  Camilo Ayala-Breton; Marisol Arias; Rafaela Espinosa; Pedro Romero; Carlos F Arias; Susana López
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

Review 3.  RNA regulation of the antiviral protein 2'-5'-oligoadenylate synthetase.

Authors:  Samantha L Schwartz; Graeme L Conn
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-04-15       Impact factor: 9.957

4.  The early interferon response to rotavirus is regulated by PKR and depends on MAVS/IPS-1, RIG-I, MDA-5, and IRF3.

Authors:  Adrish Sen; Andrea J Pruijssers; Terence S Dermody; Adolfo García-Sastre; Harry B Greenberg
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

5.  Different rotavirus strains enter MA104 cells through different endocytic pathways: the role of clathrin-mediated endocytosis.

Authors:  Michelle Gutiérrez; Pavel Isa; Claudia Sánchez-San Martin; Jimena Pérez-Vargas; Rafaela Espinosa; Carlos F Arias; Susana López
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

6.  Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action.

Authors:  A Zhou; B A Hassel; R H Silverman
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

7.  Production of Noncapped Genomic RNAs Is Critical to Sindbis Virus Disease and Pathogenicity.

Authors:  Autumn T LaPointe; V Douglas Landers; Claire E Westcott; Kevin J Sokoloski
Journal:  mBio       Date:  2020-12-01       Impact factor: 7.867

8.  Characterization of rotavirus RNAs that activate innate immune signaling through the RIG-I-like receptors.

Authors:  Dina Uzri; Harry B Greenberg
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

Review 9.  Innate immune evasion strategies of DNA and RNA viruses.

Authors:  Dia C Beachboard; Stacy M Horner
Journal:  Curr Opin Microbiol       Date:  2016-06-08       Impact factor: 7.934

10.  Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years.

Authors:  Christopher Troeger; Ibrahim A Khalil; Puja C Rao; Shujin Cao; Brigette F Blacker; Tahmeed Ahmed; George Armah; Julie E Bines; Thomas G Brewer; Danny V Colombara; Gagandeep Kang; Beth D Kirkpatrick; Carl D Kirkwood; Jason M Mwenda; Umesh D Parashar; William A Petri; Mark S Riddle; A Duncan Steele; Robert L Thompson; Judd L Walson; John W Sanders; Ali H Mokdad; Christopher J L Murray; Simon I Hay; Robert C Reiner
Journal:  JAMA Pediatr       Date:  2018-10-01       Impact factor: 16.193

View more
  1 in total

1.  Reovirus Efficiently Reassorts Genome Segments during Coinfection and Superinfection.

Authors:  Timothy W Thoner; Madeline M Meloy; Jacob M Long; Julia R Diller; James C Slaughter; Kristen M Ogden
Journal:  J Virol       Date:  2022-09-12       Impact factor: 6.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.